European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. ONON
6. AAPL
7. RTB
8. AZN
9. SPCX
10. TRMD

Go back to European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
Merck & Co. (NYSE: MRK) Delayed: 146.87 -0.28 (0.19%)
Previous Close $147.15    52 Week High $65.46 
Open $147.08    52 Week Low $47.97 
Day High $147.84    P/E 99.91 
Day Low $145.74    EPS $1.47 
Volume 31,159,364